251 related articles for article (PubMed ID: 25382829)
1. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.
Collins PW; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Blood; 2014 Nov; 124(23):3389-97. PubMed ID: 25339360
[TBL] [Abstract][Full Text] [Related]
4. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
5. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
6. Predictive immunogenicity of Refacto AF.
Delignat S; Repessé Y; Gilardin L; Dimitrov JD; Lone YC; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Jul; 20(4):486-92. PubMed ID: 24372710
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
[TBL] [Abstract][Full Text] [Related]
8. A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII.
Dubé E; Bonnefoy A; Merlen C; Castilloux JF; Cloutier S; Demers C; Sabapathy CA; St-Louis J; Vezina C; Warner M; Rivard GÉ
Haemophilia; 2018 Mar; 24(2):236-244. PubMed ID: 29388742
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
[TBL] [Abstract][Full Text] [Related]
10. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor development in non-severe haemophilia across Europe.
Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
[TBL] [Abstract][Full Text] [Related]
12. Switching treatments in haemophilia: is there a risk of inhibitor development?
Santagostino E; Auerswald G; Benson G; Dolan G; Jiménez-Yuste V; Lambert T; Ljung R; Morfini M; Remor E; Zupančić Šalek S
Eur J Haematol; 2015 Apr; 94(4):284-9. PubMed ID: 25135593
[TBL] [Abstract][Full Text] [Related]
13. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
14. Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up.
Dou X; Liu W; Poon MC; Zhang X; Wu J; Zeng X; Wu R; Hu Q; Li C; Wang X; Song X; Chen L; Zhang L; Xue F; Yang R
Br J Haematol; 2021 Mar; 192(5):900-908. PubMed ID: 33534930
[TBL] [Abstract][Full Text] [Related]
15. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.
Nakar C; Manco-Johnson MJ; Lail A; Donfield S; Maahs J; Chong Y; Blades T; Shapiro A
Haemophilia; 2015 May; 21(3):365-373. PubMed ID: 25581638
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.
Romanov V; Marcucci M; Cheng J; Thabane L; Iorio A
Thromb Haemost; 2015 Jul; 114(1):56-64. PubMed ID: 26017627
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
van den Berg HM
Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
[TBL] [Abstract][Full Text] [Related]
20. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
